Cardio-renal interaction: impact of renal function and anemia on the outcome of chronic heart failure

Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, Shlipak MG (2006) Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the anemia in chronic heart failure: outcomes and resource utilization (ANCHOR) Study. Circulation 113:2713–2723

Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Östergren J, Michelson EL, Pieper KS, Granger CB (2006) Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 27:65–75

Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39:1780–1786

Silverberg D, Wexler D, Blum M, Wollman Y, Iaina A (2003) The cardio-renal anemia syndrome: does it exist? Nephrol Dial Transplant Suppl 8:7–12

Shiba N, Matsuki M, Takahashi J, Tada T, Watanabe J, Shimokawa H (2008) Prognostic importance of chronic kidney disease in Japanese patients with chronic heart failure. Implications of the CHART Study. Circ J 72:173–178

Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson, PW (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108:2154–2169

Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M (2005) Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 68:228–236

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305

Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Modification of the modification of diet in renal disease (MDRD) study equation for Japan. Am J Kidney Dis 50:927–937

Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41–50

Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, Ura N, Kiyohara Y, Hirakata H, Moriyama T, Ando Y, Nitta K, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 11:156–163

McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441–1446

McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (2004) Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109:1004–1009

Pitsavos C, Kourlaba G, Panagiotakos DB, Kogias Y, Mantas Y, Chrysohoou C, Stefanadis C (2007) Association of creatinine clearance and in-hospital mortality in patients with acute coronary syndromes: the GREECS study. Circ J 71:9–14

Nakamura K, Okamura T, Hayakawa T, Kadowaki T, Kita Y, Ohnishi H, Saitoh S, Sakata K, Okayama A, Ueshima H; The NIPPON DATA90 research group (2006) Chronic kidney disease is a risk factor for cardiovascular death in a community-based population in Japan: NIPPON DATA90. Circ J 70:954–959

Senni M, Redfield MM (2001) Heart failure with preserved systolic function: a different natural history? J Am Coll Cardiol 38:1277–1282

Tsuchihashi M, Tsutsui H, Kodama K, Kasagi F, Takeshita A (2000) Clinical characteristics and prognosis of hospitalized patients with congestive heart failure, a study in Fukuoka, Japan. Circ J 64:953–959

Tsutsui H, Tsuchihashi M, Takeshita A (2001) Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 88:530–533

Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T; for the Candesartan Antihypertensive Survival Evaluation in Japan trial group (2008) Effects of candesartan compared with amlodipine in hypertensive patients trial with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 51:393–398

Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033

Felker GM, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheorghiade M, O’Connor CM (2003) Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 92:625–628

Felker GM, Adams KF Jr, Gattis WA, O’Connor CM (2004) Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 44:959–966

Silverberg DS, Wexler D, Iaina A (2004) The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J Nephrol 17:749–761

Silverberg DS, Wexler D, Blum B, Iaina A (2003) Anemia in chronic kidney disease and congestive heart failure. Blood Purif 21:124–130

Coats AJ (2004) Anaemia and heart failure. Heart 90:977–979

Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37:1775–1780

Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A (2000) The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35:1737–1744

Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R (2002) B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105:2392–2397

Maeda K, MD, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M (2000) High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 36:1587–1593

Ueno H, Nakayama M, Kojima S, Kusuhara K, Nagayoshi Y, Yamamuro M, Nishijima T, Usuku H, Kaikita K, Sumida H, Yamabe H, Sugiyama S, Yoshimura M, Ogawa H (2008) The synergistic combined effect of anemia with high plasma levels of Btype natriuretic peptide significantly predicts an enhanced risk for major adverse cardiac events. Heart Vessels 23:243–248

Karavidas A, Lazaros G, Matsakas E, Farmakis D, Parissis J, Paraskevaidis IA, Michailidis C, Avramidis D, Zacharoulis A, Arapi S, Kaoukis A, Zacharoulis A (2008) Clinical value of B-type natriuretic peptide for the assessment of left ventricular filling pressures in patients with systolic heart failure and inconclusive tissue Doppler indexes. Heart Vessels 23:181–186